here's a potential little gem for you myriad of guys and gals who like "diddy" companies ...... preliminary 12 month results to 30/11/06 due Tuesday 28 Feb.



Founded: November 2003
Ownership: Publicly traded on AiM of London Stock Exchange
Personnel: 25

Revenues:
Proximagen provides highly specialized laboratory services for pharmaceutical and biotech companies to support the discovery and development of novel therapeutic approaches to neurological disorders. Proximagen's personnel have particular expertise in neurodegenerative conditions, including Parkinson's disease and Alzheimer's disease.

Profile:
Proximagen is a neuroscience research company focused on drug development for neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.


The shares are tightly held, so don't expect to be able to trade in "swathes" ...... maximum is probably only 2500/5000.

USL Pharma International close to acquiring Proximagen Group
StockMarketWire.com
USL Pharma International's recommended offer for Proximagen Group looks likely to go ahead.

The High Court has made an order confirming the reduction of capital in connection with the scheme by which USL is implementing the acquisition.

Proximagen has made an application to the London Stock Exchange for the cancellation of the admission to trading of its shares on AIM effective from 7.00 a.m. tomorrow